Using Neuroplasticity-Based Computerized Training to Improve Emotion Regulation in Bipolar Disorder (BRAINS)
NCT ID: NCT05683431
Last Updated: 2023-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2019-03-22
2021-12-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Emotion Recognition Modification for Bipolar Disorder
NCT02613104
Functional Connectivity in Mood Regulating Circuit In Bipolar Depression and Mania
NCT00457054
Reducing Medical Risks in Individuals With Bipolar Disorder - Full Study
NCT00746343
Treatment to Enhance Cognition in Bipolar Disorder
NCT01470781
Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder
NCT03336918
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Individuals with bipolar disorder have deficits on both behavioral and neural measures of CCE (Phillips and Swartz 2014). Typical CCE tasks require identifying a target stimulus (e.g. word, facial expression, etc.) while inhibiting irrelevant or conflicting emotional information. During such tasks, people with bipolar disorder have difficulty controlling the distracting influence of irrelevant emotional information. These behavioral deficits are associated with neural abnormalities in both cognitive control and emotion processing neural systems. These neural abnormalities are characterized, primarily, by abnormally low activity in the cognitive control network, particularly the lateral prefrontal cortex, and abnormally high activity in emotion processing regions, particularly the amygdala and ventral striatum. Bipolar disorder is also associated with abnormalities in structural elements of these neural systems, including abnormal gray matter volume and white matter tracks. Research suggests that deficits in CCE and related neural networks are an underlying cause of characteristic symptoms of bipolar disorder, including emotional lability, extreme mood states, and disinhibited behavior (reviewed in Phillips and Swartz 2014 and Wegbreit et al. 2014). These findings point to CCE as a clinically relevant and scientifically tractable treatment target for bipolar.
Study Design \& Specific Aims The primary goal of this project is to investigate, in young adults with bipolar disorder, whether a computerized training program of CCE exercises improves CCE as measured with a range of assessment tasks that require flexible deployment of CCE skills. The long-term goal is to evaluate whether CCE training improves emotion regulation and maladaptive mood symptoms.The overarching hypothesis is that training-related improvement in CCE will facilitate improvements in emotion regulation across multiple contexts, and, thus, reduce the symptoms and consequences of emotion dysregulation in bipolar.
The second goal of the project is to collect pilot data, establish feasibility, and gather other information necessary to acquire federal funding for a large-scale, double-blind, randomized control trial of CCE training for bipolar. To ensure subsequent federal funding, the current project design is consistent with an experimental medicine model and NIMH guidelines for clinical trial research. NIMH has a progressive funding structure for the development of novel biological or behavioral interventions. The current project is designed to satisfy requirements of the first phase in this funding structure. Consistent with NIMH guidelines for exploratory clinical trials, the current project has a clearly defined treatment target (i.e. CCE skills) and a theoretical model regarding how the target mechanism is related to psychopathology. The main purpose of an exploratory trial is to verify 'target engagement' - i.e. that the intervention influences the intended treatment target. It is not necessary to have a comparison group. However, evidence of target engagement in a single, active treatment group is a requirement for obtaining more advanced levels of NIMH funding. The current project will evaluate target engagement in a single group that completes CCE training. The study maximize the potential to detect target engagement by using behavioral and neural measures of CCE that are valid, reliable, and sensitive to treatment-related improvement.
Another purpose of the exploratory phase is to gather information about feasibility, tolerability, dose, and other potential factors that could influence treatment effectiveness, patient compliance, and broad implementation, particularly in non-academic settings. Data from the current project will address these issues and provide salient information to guide treatment development and implementation in the next phase. This information includes data on participants' motivation to continue training, enjoyment of training exercises, compliance to the training schedule (e.g. number of days missed, real or perceived obstacles to training, strategies that enhance motivation and compliance, etc.).
In summary, the investigators will conduct an exploratory clinical trial that is consistent with NIMH guidelines for clinical trial research and addresses the goals of an initial (first phase) NIMH grant for novel interventions. Results from the study will provide the pilot data necessary to obtain additional funding for the next phase of treatment development - i.e. An "Exploratory/Developmental Grant for Novel Interventions Phase II (R33)" or a "Confirmatory Efficacy Clinical Trial of Non-Pharmacological Interventions for Mental Disorders (R01)".
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cognitive Control of Emotion (CCE) Training
Mobile (iphone/ipad) "App" with game-like exercises designed to improve Cognitive Control of Emotion (CCE), i.e. the ability to control the influence of emotional information on behavior. Participants do 20 sessions (approximately 30min each), over 4 weeks.
Cognitive Control of Emotion (CCE) Training
Training consists of game-like exercises using a software program developed in collaboration with PositScience Corporation (using BrainHQ platform ) - which has exercises targeting cognition and social cognition. The CCE training program incorporates characteristics that optimize learning-induced neuroplasticity - most importantly, exercises are short \& rewarding, adapt to individual skill-level, and become increasingly difficult as performance improves. There are 5 CCE exercises that are organized in half-hour sessions and proceed in a predetermined sequence.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cognitive Control of Emotion (CCE) Training
Training consists of game-like exercises using a software program developed in collaboration with PositScience Corporation (using BrainHQ platform ) - which has exercises targeting cognition and social cognition. The CCE training program incorporates characteristics that optimize learning-induced neuroplasticity - most importantly, exercises are short \& rewarding, adapt to individual skill-level, and become increasingly difficult as performance improves. There are 5 CCE exercises that are organized in half-hour sessions and proceed in a predetermined sequence.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. be between 18 and 30 years old, inclusive.
2. have learned English before the age of 12.
3. demonstrate adequate decisional capacity, in the judgment of the consenting study staff member, to make a choice about participating in this research study.
1. meet criteria for Bipolar I Disorder, that is not better explained by another psychiatric disorder, including but not limited to a psychotic disorder, substance-induced bipolar disorder, and bipolar disorder due to a medical condition as defined by DSM5 criteria and confirmed by the SCID.
2. have an onset of Bipolar I Disorder within the past five (5) years, with onset being determined by the first time the subject met DSM-5 criteria for Bipolar I Disorder in their lifetime, as determined by the SCID and regardless of a formal diagnosis.
3. receive a score of less than eight (8) on the YMRS and a score of less than 15 on the MADRS according to the Bipolar Inventory of Symptoms Scale (BISS) at the consent visit.
4. have the visual, auditory, and motor capacity to use the computerized intervention in the judgment of the consenting study staff person.
At the time of the consent, the subject MUST:
1\. have no evidence of past history of manic and/or hypomanic episodes as determined by the clinician and described by DSM Criterion A for each type of episode
1. Manic Episode, Criterion A: A distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased activity or energy, lasting at least 1 week and present most of the day, nearly every day (or any duration if hospitalization is necessary).
2. Hypomanic Episode, Criterion A: A distinct period of abnormally and persistently elevated, expansive, or irritable mood and abnormally and persistently increased activity or energy, lasting at least 4 consecutive days and present most of the day, nearly every day.
Exclusion Criteria
1. have a history of mental retardation (determined by an IQ\<70 based on the WRAT or an equivalent brief IQ test) or pervasive developmental disorder; or other neurological disorder (e.g., epilepsy, Parkinson's disease), or another major medical illness.
2. have a current or recent (within past three months) substance use disorder that is characterized as severe as defined by the DSM-5 criteria and confirmed by the SCID-I or by a score of 37 or more on the AADIS.
3. have had, according to the Traumatic Brain Injury (TBI) interview, a moderate or severe TBI where consciousness is lost for 30 minutes or more, or had three or more mild TBIs where consciousness was lost for more than five minutes on each occasion.
4. have severe and persistent ADHD that was diagnosed in childhood (before the age of 12). Subjects who received a diagnosis of ADHD with onset concurrent with bipolar disorder and/or after age 12, will NOT be excluded.
5. have answered 'yes' to Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the C-SSRS or have answered 'yes' to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act or behavior) on the C-SSRS "Suicidal Behavior" portion shall be excluded from the study if ideation or behavior occurred within two months of consent. Subjects excluded for this reason will be referred for appropriate treatment.
Additionally, subjects who appear to be intoxicated or under the influence of a controlled substance on any day of assessment must be rescheduled or discontinued based upon the discretion of the staff evaluator.
At the time of the consent, the subject should NOT:
1. be in an active illness phase that requires monitoring, intervention, and/or increased psychiatric oversight. Increased psychiatric oversight, may include, but is not limited to:
1. having had a psychiatric hospitalization in the eight (8) weeks prior to consent.
2. changes in psychiatric medication in the eight (8) weeks prior to consent.
3. experiencing four (4) or more episodes of mania and/or depression within the 12 months (i.e. rapid cycling) prior to consent.
2. meet DSM-5 criteria for an episode of mania, hypomania, or depression in the eight (8) weeks prior to consent.
3. have a medication regime consisting of more than four (4) psychotropic medications OR with a high anticholinergic load, defined as benzotropine equivalent greater than two (2) milligrams (Minzenburg et al 2004).
4. have a history of electric convulsive therapy (ECT), transcranial magnetic stimulation (TMS), or deep brain stimulation (DBS).
5. have been treated within 5 years of the date of consent with a computer-based cognitive training program
6. be participating in a concurrent clinical trial that, in the judgment of the staff evaluator could affect the outcome of this one.
At the time of the consent, the subject should NOT:
1. meet for a DSM psychiatric disorder, in the last three months
2. have met for a major depressive episode (MDE) in the last year and/or three or more MDEs in their lifetime
3. be receiving current behavioral treatment focusing on emotion regulation or mood problems (e.g. anger management) and/or psychopharmacological treatment
18 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Ryan Licht Sang Bipolar Foundation
UNKNOWN
Rush University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christine I Hooker, PhD
Role: PRINCIPAL_INVESTIGATOR
Rush University Medical Center
Kristen M Haut, PhD
Role: STUDY_DIRECTOR
Rush University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rush University Medical Center
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Altman EG, Hedeker D, Peterson JL, Davis JM. The Altman Self-Rating Mania Scale. Biol Psychiatry. 1997 Nov 15;42(10):948-55. doi: 10.1016/S0006-3223(96)00548-3.
Arbuthnott K, Frank J. Trail making test, part B as a measure of executive control: validation using a set-switching paradigm. J Clin Exp Neuropsychol. 2000 Aug;22(4):518-28. doi: 10.1076/1380-3395(200008)22:4;1-0;FT518.
Bowden CL, Singh V, Thompson P, Gonzalez JM, Katz MM, Dahl M, Prihoda TJ, Chang X. Development of the bipolar inventory of symptoms scale. Acta Psychiatr Scand. 2007 Sep;116(3):189-94. doi: 10.1111/j.1600-0447.2006.00955.x.
Burdick KE, Ketter TA, Goldberg JF, Calabrese JR. Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design. J Clin Psychiatry. 2015 Mar;76(3):e342-50. doi: 10.4088/JCP.14cs09399.
Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.
Carver CS, Ganellen RJ. Depression and components of self-punitiveness: high standards, self-criticism, and overgeneralization. J Abnorm Psychol. 1983 Aug;92(3):330-7. doi: 10.1037//0021-843x.92.3.330. No abstract available.
Carver CS, Johnson SL. Tendencies Toward Mania and Tendencies Toward Depression Have Distinct Motivational, Affective, and Cognitive Correlates. Cognit Ther Res. 2009 Dec;33(6):552-569. doi: 10.1007/s10608-008-9213-y.
Carver, C.S., White, T.L., 1994. Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: the BIS/BAS scales. J. Pers. Soc. Psychol. 67, 319-333.
Carver CS, Scheier MF, Weintraub JK. Assessing coping strategies: a theoretically based approach. J Pers Soc Psychol. 1989 Feb;56(2):267-83. doi: 10.1037//0022-3514.56.2.267.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17042901
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.